Phase 3 Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing to sign a consent form and complete the study as planned
- People aged between 18 and 80 years old
- People with a general health and activity level rated as fully active or with only minor limitations (this is measured using a standard scale called ECOG — confirm with trial site)
- People who have not had lung cancer surgery before
- People confirmed to have a specific type of lung cancer called invasive lung adenocarcinoma, identified either during or after surgery
- People whose lung nodule appears mostly as "ground glass" on imaging (a hazy, cloud-like appearance rather than a solid mass)
- People whose nodule has a solid-to-total size ratio between 0 and 0.5, and a total tumour size between 2 and 3 centimetres
- People whose cancer has not spread to nearby lymph nodes or to other parts of the body
- People whose tumour a surgeon has assessed as being able to be fully removed
- People who have not received chemotherapy or radiotherapy before
Who may not be able to join:
- People whose nodule does not fall within the required size range (2–3 cm) or solid-to-total ratio (0–0.5)
- People whose tumour a surgeon has assessed as unable to be fully removed
- People whose lung cancer type has not been confirmed as adenocarcinoma through cell or tissue testing
- People who have previously had lung cancer surgery
- People who have previously received radiotherapy or chemotherapy
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Haiquan Chen, M.D., Fudan University
Phone: +86-13122677592
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
5-year disease-free survival
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.